March is Blood Clot Awareness Month, and health officials are raising concerns about the risks associated with venous thrombosis, which is a blood clot in a vein. This is a condition that impacts ...

Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...

Most patients in both groups also achieved normal hemostasis—that is, normal blood clotting and repair of damaged blood vessels —after bentracimab treatment." ...

The global hemostasis products market is poised for significant growth in the coming decade, according to the latest market projections. Valued at USD 1.58 billion in 2023, the market is anticipated ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...